File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy versus radiotherapy for stage I-II intermediate grade non-Hodgkin's lymphomas

TitleChemotherapy versus radiotherapy for stage I-II intermediate grade non-Hodgkin's lymphomas
Authors
KeywordsIntermediate Grade
Non-Hodgkin's Lymphoma
Stage I And Ii
Issue Date1991
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
Citation
Clinical Oncology, 1991, v. 3 n. 6, p. 335-339 How to Cite?
AbstractThe clinical outcome of 149 patients with Stage I-II intermediate grade non-Hodgkin's lymphomas was analysed. There were 77 (52%) males and 72 (48%) females. Their median age was 58 years. Eighty patients (54%) had Stage I disease and 69 (46%) Stage II. Twenty-nine (20%) of them received radiotherapy only, 75 (50%) doxorubicin-containing chemotherapeutic regimens and 45 (30%) other less intensive chemotherapy. Sixty-two patients had additional radiotherapy following chemotherapy. Patients receiving other less intensive chemotherapy were significantly older (P = 0.0001) and those receiving radiotherapy alone had a significantly higher proportion of Stage I disease (P = 0.007.). Patients receiving less intensive chemotherapy had a significantly low complete response (CR) rate. Patients receiving radiotherapy alone had a significantly high relapse rate and low disease-free survival following CR. However, there was no significant difference in overall survival regardless of the mode of therapy. This lack of survival advantage might be related to the effective salvage chemotherapy in some of the radiotherapy failures and the occasional chemotherapy-related mortality Additional radiotherapy following chemotherapy did not appear to give further benefit. © 1991 The Royal College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/161906
ISSN
2022 Impact Factor: 3.4
2020 SCImago Journal Rankings: 1.037

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorChoy, Den_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorLoke, SLen_US
dc.date.accessioned2012-09-05T05:15:57Z-
dc.date.available2012-09-05T05:15:57Z-
dc.date.issued1991en_US
dc.identifier.citationClinical Oncology, 1991, v. 3 n. 6, p. 335-339en_US
dc.identifier.issn0936-6555en_US
dc.identifier.urihttp://hdl.handle.net/10722/161906-
dc.description.abstractThe clinical outcome of 149 patients with Stage I-II intermediate grade non-Hodgkin's lymphomas was analysed. There were 77 (52%) males and 72 (48%) females. Their median age was 58 years. Eighty patients (54%) had Stage I disease and 69 (46%) Stage II. Twenty-nine (20%) of them received radiotherapy only, 75 (50%) doxorubicin-containing chemotherapeutic regimens and 45 (30%) other less intensive chemotherapy. Sixty-two patients had additional radiotherapy following chemotherapy. Patients receiving other less intensive chemotherapy were significantly older (P = 0.0001) and those receiving radiotherapy alone had a significantly higher proportion of Stage I disease (P = 0.007.). Patients receiving less intensive chemotherapy had a significantly low complete response (CR) rate. Patients receiving radiotherapy alone had a significantly high relapse rate and low disease-free survival following CR. However, there was no significant difference in overall survival regardless of the mode of therapy. This lack of survival advantage might be related to the effective salvage chemotherapy in some of the radiotherapy failures and the occasional chemotherapy-related mortality Additional radiotherapy following chemotherapy did not appear to give further benefit. © 1991 The Royal College of Radiologists.en_US
dc.languageengen_US
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clonen_US
dc.relation.ispartofClinical Oncologyen_US
dc.subjectIntermediate Gradeen_US
dc.subjectNon-Hodgkin's Lymphomaen_US
dc.subjectStage I And Iien_US
dc.titleChemotherapy versus radiotherapy for stage I-II intermediate grade non-Hodgkin's lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1742233-
dc.identifier.scopuseid_2-s2.0-0026246524en_US
dc.identifier.volume3en_US
dc.identifier.issue6en_US
dc.identifier.spage335en_US
dc.identifier.epage339en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridChoy, D=8663654500en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridLoke, SL=7006559512en_US
dc.identifier.issnl0936-6555-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats